Unither Développement Bordeaux, ZA Tech Espace, av Toussaint Catros, Le Haillan 33185, France; Département Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), AP-HP, 7 rue du fer à moulin, Paris 75005, France; Université de Paris, UTCBS, CNRS, INSERM, Faculté de Pharmacie, 4 av de l'observatoire, Paris 75006, France(1).
Unither Pharmaceuticals, 3-5 rue St-Georges, Paris 75009, France.
Int J Pharm. 2020 Jan 25;574:118734. doi: 10.1016/j.ijpharm.2019.118734. Epub 2019 Nov 6.
Achieving drug delivery at the ocular level encounters many challenges and obstacles. In situ gelling delivery systems are now widely used for topical ocular administration and recognized as a promising strategy to improve the treatment of a wide range of ocular diseases. The present work describes the formulation and evaluation of a mucoadhesive and ion-activated in situ gelling delivery system based on gellan gum and hydroxyethylcellulose for the delivery of phenylephrine and tropicamide. First, physico-chemical characteristics were assessed to ensure suitable properties regarding ocular administration. Then, rheological properties such as viscosity and gelation capacity were determined. Gelation capacity of the formulations and the effect of hydroxyethylcellulose on viscosity were demonstrated. A new rheological method was developed to assess the gel resistance under simulated eye blinking. Afterward, mucoadhesion was evaluated using tensile strength test and rheological synergism method in both rotational and oscillatory mode allowing mucoadhesive properties of hydroxyethylcellulose to be point out. Finally, residence time on the ocular surface was investigated in vivo, using cyanine 5.5 dye as a fluorescent marker entrapped in the in situ gelling delivery systems. Residence performance was studied by non-invasive optical imaging on vigilant rabbits, allowing eye blinking and nasolacrimal drainage to occur physiologically. Fluorescence intensity profiles pointed out a prolonged residence time on the ocular surface region for the developed formulations compared to conventional eye drops, suggesting in vitro / in vivo correlations between rheological properties and in vivo residence performances.
在眼部实现药物输送会遇到许多挑战和障碍。原位凝胶给药系统现在广泛用于局部眼部给药,被认为是改善多种眼部疾病治疗的有前途的策略。本工作描述了一种基于结冷胶和羟乙基纤维素的粘弹性和离子激活的原位凝胶给药系统,用于传递苯肾上腺素和托吡卡胺的制剂和评价。首先,评估物理化学特性以确保适合眼部给药的特性。然后,确定流变学特性,如粘度和凝胶形成能力。证明了配方的凝胶形成能力以及羟乙基纤维素对粘度的影响。开发了一种新的流变学方法来评估模拟眨眼下的凝胶阻力。随后,使用拉伸强度试验和旋转和振荡模式下的流变协同作用方法评估粘膜粘附性,从而指出羟乙基纤维素的粘膜粘附特性。最后,通过将花青 5.5 染料作为荧光标记物包封在原位凝胶给药系统中,在体内研究了在眼部表面的停留时间。通过警惕兔子的非侵入性光学成像研究停留性能,允许眨眼和鼻泪管生理排水。荧光强度曲线指出,与常规眼药水相比,开发的制剂在眼部表面区域的停留时间更长,表明流变学特性和体内停留性能之间存在体外/体内相关性。